Page last updated: 2024-10-22

amsacrine and Skin Neoplasms

amsacrine has been researched along with Skin Neoplasms in 5 studies

Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.

Skin Neoplasms: Tumors or cancer of the SKIN.

Research Excerpts

ExcerptRelevanceReference
"In a phase II study 20 patients with measurable metastatic melanoma were treated with amsacrine 120 mg/m2 every 3 weeks."7.67Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene. ( Bishop, J; Coates, AS; Mann, GJ; Raghavan, D, 1986)
"In a phase II study 20 patients with measurable metastatic melanoma were treated with amsacrine 120 mg/m2 every 3 weeks."3.67Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene. ( Bishop, J; Coates, AS; Mann, GJ; Raghavan, D, 1986)
"Amsacrine is an antineoplastic drug used in the treatment of acute adult leukemias."1.29Carcinogenicity of the anticancer topoisomerase inhibitor, amsacrine, in Wistar rats. ( Courtney, CL; Gough, AW; Graziano, MJ; Kheoh, T; Meierhenry, EF; Pegg, DG, 1996)
"Leukopenia was the dose-limiting toxicity with 7."1.27The treatment of melanoma with m-AMSA. A Cancer and Leukemia Group B phase II study. ( Amrein, PC; Carey, RW; Coleman, M; Green, MR; Holland, JF; Kennedy, BJ; Poulin, RF; Richards, F; Weil, M; Weinberg, V, 1984)
"Leukopenia was found to be dose-limiting; thrombocytopenia and anemia were also observed."1.26Phase II study of m-AMSA in advances malignant melanoma. ( Arseneau, JC; Kuperminc, M; Probert, JC; Wolter, JM, 1982)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19904 (80.00)18.7374
1990's1 (20.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Amrein, PC1
Poulin, RF1
Coleman, M1
Richards, F1
Weil, M1
Kennedy, BJ1
Carey, RW1
Green, MR1
Holland, JF1
Weinberg, V1
Legha, SS1
Hall, SW1
Powell, KC1
Burgess, MA1
Benjamin, RS1
Gutterman, JU1
Bodey, GP1
Arseneau, JC1
Wolter, JM1
Probert, JC1
Kuperminc, M1
Graziano, MJ1
Courtney, CL1
Meierhenry, EF1
Kheoh, T1
Pegg, DG1
Gough, AW1
Coates, AS1
Bishop, J1
Mann, GJ1
Raghavan, D1

Other Studies

5 other studies available for amsacrine and Skin Neoplasms

ArticleYear
The treatment of melanoma with m-AMSA. A Cancer and Leukemia Group B phase II study.
    American journal of clinical oncology, 1984, Volume: 7, Issue:3

    Topics: Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Drug Evaluation; Female; Humans; Leuk

1984
Phase II study of 4'-(9-acridinylamino) methanesulfon-m- anisidide (AMSA) in metastatic melanoma.
    Cancer clinical trials, 1980,Summer, Volume: 3, Issue:2

    Topics: Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Drug Administration Schedule; Drug Ev

1980
Phase II study of m-AMSA in advances malignant melanoma.
    American journal of clinical oncology, 1982, Volume: 5, Issue:4

    Topics: Adult; Aged; Aminoacridines; Amsacrine; Drug Evaluation; Female; Humans; Leukopenia; Male; Melanoma;

1982
Carcinogenicity of the anticancer topoisomerase inhibitor, amsacrine, in Wistar rats.
    Fundamental and applied toxicology : official journal of the Society of Toxicology, 1996, Volume: 32, Issue:1

    Topics: Amsacrine; Animals; Antineoplastic Agents; Carcinogenicity Tests; Carcinogens; Drug Evaluation, Prec

1996
Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene.
    European journal of cancer & clinical oncology, 1986, Volume: 22, Issue:1

    Topics: Aminoacridines; Amsacrine; Anthracenes; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Fema

1986